Senti Biosciences Reports <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Financial Results: Cash Holdings Decrease to $21.6M, R&D Expenses Rise by $0.8M
Senti Biosciences, Inc. (Nasdaq: SNTI), a clinical-stage biotechnology company, has released its financial results for the second quarter of 2025. As of June 30, 2025, the company reported cash and cash equivalents of approximately $21.6 million, down from $48.3 million at the end of 2024. Research and development expenses increased to $10.0 million from $9.2 million in the same period in 2024, primarily due to a rise in external services and supplies costs. In corporate updates, Senti Bio has completed the dose-finding phase and confirmed the recommended Phase 2 dose in its ongoing Phase 1 clinical trial of SENTI-202 for treating relapsed/refractory hematologic malignancies, including acute myeloid leukemia $(AML.AU)$. The SENTI-202 program has been granted U.S. FDA Orphan Drug Designation for AML treatment. Additionally, the company received a $1.0 million tranche from a California Institute for Regenerative Medicines grant to advance the clinical development of SENTI-202. The leadership team was strengthened with the appointments of Bryan Baum to the Board of Directors and Dr. James B. Trager to the Scientific Advisory Board. Senti Bio continues to engage with the investor and scientific communities through various events and conferences, aiming to increase visibility and awareness of its innovations in next-generation cell and gene therapies.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senti Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001854270-25-000088), on August 07, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.